Femlyv Kit
Product Images NDC 72495-601

This is a data table showing the number of women with a blood clot out of 10,000 women years based on pregnancy and postpartum periods for both non-users and users of COC (combined oral contraceptives). It provides information on the risks of blood clots associated with these factors.*

This text contains information on various studies evaluating the risk of breast cancer associated with combined oral contraceptives (COC). The studies mentioned include NICHD Women's Care Study, French E3N cohort Study, Shanghal Women's Health Study, The Nurses' Health Study I, Oxford Family Planning Study, and Danish Sex Hormone Register Study. The text shows comparisons between women who have ever used COC and those who have never used it, as well as the comparison between current COC users and never-users. The text also includes effect estimates such as OR (Odds Ratio), RR (Relative Risk), and HR (Hazard Ratio) along with corresponding confidence intervals.*

This information outlines different methods of birth control and their effectiveness in preventing pregnancies. It categorizes the number of pregnancies per 100 women each year and lists various options such as implants, injections, intrauterine devices, sterilization, birth control pills, condoms, and more. The text also suggests avoiding sex during a woman's most fertile days as an additional method.*

This text provides instructions for starting with birth control pills depending on whether your period starts on a Sunday or another day of the week. It indicates how to properly label and take the pills for Sunday starters and day 1 starters. The direction for taking the pills is clearly specified as being from left to right each week.*

This text appears to contain information about pharmaceutical products, specifically describing two types of orally disintegrating tablets named "FEMYLVTM" and detailing their composition of norethindrone acetate and ethinyl estradiol. The tablets provide 24 days of active therapy in a 28-day regimen. The tablets are available in doses of 1mg/0.02mg.*

A description is not available for the provided text.*

The text provided appears to be a description of a medication called FEMLYV™, a 28-day regimen of orally disintegrating tablets used for active therapy. The tablets contain Norethindrone Acetate and Ethinyl Estradiol and are taken daily for 28 days as directed by a physician. The medication is not child-resistant, so it should be kept out of reach of children. It is manufactured by Pathean Inc and distributed by Millicent US Inc. FEMLYV™ is a registered trademark of Milicent Puerto Rico LLC. The tablets should be stored at a temperature range of 68°F to 77°F and excursions permitted to 59°F to 86°F. Adverse reactions should be reported to Milicent or the FDA.*